Malvern Biotech Ocugen to Present New Eye Gene Therapy Data
MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) will present 12-month Phase 2 results for its OCU410 gene therapy in geographic atrophy at a scientific meeting in September, putting new clinical …
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data Read More